Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 69 entries
Sorted by: Best Match Show Resources per page
Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review.

Nagoya journal of medical science

Emori M, Matsumoto Y, Murahashi Y, Yoshida M, Nishida Y.
PMID: 34916712
Nagoya J Med Sci. 2021 Nov;83(4):673-681. doi: 10.18999/nagjms.83.4.673.

The efficacy and safety of cyclooxygenase 2 (COX2) inhibitors for the treatment of desmoid-type fibromatosis (DF) are unclear. Therefore, we systematically reviewed related literature to assess the efficacy and safety of COX2 inhibitors for DF treatment. We searched pertinent...

Cite
Emori M, Matsumoto Y, Murahashi Y, et al. Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review. Nagoya J Med Sci. 2021;83(4):673-681doi: 10.18999/nagjms.83.4.673.
Emori, M., Matsumoto, Y., Murahashi, Y., Yoshida, M., & Nishida, Y. (2021). Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review. Nagoya journal of medical science, 83(4), 673-681. https://doi.org/10.18999/nagjms.83.4.673
Emori, Makoto, et al. "Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review." Nagoya journal of medical science vol. 83,4 (2021): 673-681. doi: https://doi.org/10.18999/nagjms.83.4.673
Emori M, Matsumoto Y, Murahashi Y, Yoshida M, Nishida Y. Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review. Nagoya J Med Sci. 2021 Nov;83(4):673-681. doi: 10.18999/nagjms.83.4.673. PMID: 34916712; PMCID: PMC8648529.
Copy Download .nbib Format: NLM
A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD.

Cardiology in the young

Thompson EJ, Foote HP, Li JS, Rotta AT, Goldenberg NA, Hornik CP.
PMID: 34986908
Cardiol Young. 2022 Jan 06;1-11. doi: 10.1017/S1047951121005205. Epub 2022 Jan 06.

OBJECTIVES: To determine the optimal antithrombotic agent choice, timing of initiation, dosing and duration of therapy for paediatric patients undergoing cardiac surgery with cardiopulmonary bypass.METHODS: We used PubMed and EMBASE to systematically review the existing literature of clinical trials...

Cite
Thompson EJ, Foote HP, Li JS, et al. A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD. Cardiol Young. 2022;1-11doi: 10.1017/S1047951121005205.
Thompson, E. J., Foote, H. P., Li, J. S., Rotta, A. T., Goldenberg, N. A., & Hornik, C. P. (2022). A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD. Cardiology in the young, 1-11. https://doi.org/10.1017/S1047951121005205
Thompson, Elizabeth J, et al. "A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD." Cardiology in the young vol. (2022): 1-11. doi: https://doi.org/10.1017/S1047951121005205
Thompson EJ, Foote HP, Li JS, Rotta AT, Goldenberg NA, Hornik CP. A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD. Cardiol Young. 2022 Jan 06;1-11. doi: 10.1017/S1047951121005205. Epub 2022 Jan 06. PMID: 34986908.
Copy Download .nbib Format: NLM
Reducing prostaglandin E2 production to raise cancer immunogenicity.

Oncoimmunology

Zelenay S, Reis e Sousa C.
PMID: 27467936
Oncoimmunology. 2016 Jan 04;5(5):e1123370. doi: 10.1080/2162402X.2015.1123370. eCollection 2016 May.

Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E2 (PGE2), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE2 by cancer cells dominantly enables progressive...

Cite
Zelenay S, Reis e Sousa C. Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology. 2016;5(5):e1123370doi: 10.1080/2162402X.2015.1123370.
Zelenay, S., & Reis e Sousa, C. (2016). Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology, 5(5), e1123370. https://doi.org/10.1080/2162402X.2015.1123370
Zelenay, Santiago, and Reis e Sousa, Caetano. "Reducing prostaglandin E2 production to raise cancer immunogenicity." Oncoimmunology vol. 5,5 (2016): e1123370. doi: https://doi.org/10.1080/2162402X.2015.1123370
Zelenay S, Reis e Sousa C. Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology. 2016 Jan 04;5(5):e1123370. doi: 10.1080/2162402X.2015.1123370. eCollection 2016 May. PMID: 27467936; PMCID: PMC4910741.
Copy Download .nbib Format: NLM
Rectal Acetaminophen Improves Shunt Volume and Reduces Patent Ductus Arteriosus Ligation in Extremely Preterm Infants.

American journal of perinatology

Castaldo MP, Neary E, Bischoff AR, Weisz DE, Jain A, Giesinger RE, McNamara PJ.
PMID: 34583409
Am J Perinatol. 2021 Sep 28; doi: 10.1055/s-0041-1735214. Epub 2021 Sep 28.

OBJECTIVE:  An alternative therapy for preterm infants with a hemodynamically significant patent ductus arteriosus (hsPDA) is needed when cyclooxygenase inhibitors fail or where treatment is contraindicated due to coexisting renal failure, necrotizing enterocolitis, and/or intestinal perforation. No studies have...

Cite
Castaldo MP, Neary E, Bischoff AR, et al. Rectal Acetaminophen Improves Shunt Volume and Reduces Patent Ductus Arteriosus Ligation in Extremely Preterm Infants. Am J Perinatol. 2021;doi: 10.1055/s-0041-1735214.
Castaldo, M. P., Neary, E., Bischoff, A. R., Weisz, D. E., Jain, A., Giesinger, R. E., & McNamara, P. J. (2021). Rectal Acetaminophen Improves Shunt Volume and Reduces Patent Ductus Arteriosus Ligation in Extremely Preterm Infants. American journal of perinatology, . https://doi.org/10.1055/s-0041-1735214
Castaldo, Michael P, et al. "Rectal Acetaminophen Improves Shunt Volume and Reduces Patent Ductus Arteriosus Ligation in Extremely Preterm Infants." American journal of perinatology vol. (2021). doi: https://doi.org/10.1055/s-0041-1735214
Castaldo MP, Neary E, Bischoff AR, Weisz DE, Jain A, Giesinger RE, McNamara PJ. Rectal Acetaminophen Improves Shunt Volume and Reduces Patent Ductus Arteriosus Ligation in Extremely Preterm Infants. Am J Perinatol. 2021 Sep 28; doi: 10.1055/s-0041-1735214. Epub 2021 Sep 28. PMID: 34583409.
Copy Download .nbib Format: NLM
Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?.

Canadian family physician Medecin de famille canadien

Kvern B.
PMID: 12371303
Can Fam Physician. 2002 Sep;48:1449-51.

No abstract available.

Cite
Kvern B. Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?. Can Fam Physician. 2002;48:1449-51
Kvern, B. (2002). Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?. Canadian family physician Medecin de famille canadien, 481449-51.
Kvern, Brent. "Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?." Canadian family physician Medecin de famille canadien vol. 48 (2002): 1449-51.
Kvern B. Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?. Can Fam Physician. 2002 Sep;48:1449-51. PMID: 12371303; PMCID: PMC2214104.
Copy Download .nbib Format: NLM
Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases.

Case reports in dermatology

Garofalo V, Ventura A, Mazzilli S, Diluvio L, Bianchi L, Toti L, Tisone G, Milani M, Campione E.
PMID: 29282394
Case Rep Dermatol. 2017 Oct 20;9(3):211-216. doi: 10.1159/000481770. eCollection 2017.

Organ transplant recipient (OTR) subjects are at high risk of skin cancer such as squamous cell carcinoma and basal cell carcinoma. Actinic keratosis (AK) is considered the precursor of these non-melanoma skin cancers. Sun protection is mandatory in subjects...

Cite
Garofalo V, Ventura A, Mazzilli S, et al. Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases. Case Rep Dermatol. 2017;9(3):211-216doi: 10.1159/000481770.
Garofalo, V., Ventura, A., Mazzilli, S., Diluvio, L., Bianchi, L., Toti, L., Tisone, G., Milani, M., & Campione, E. (2017). Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases. Case reports in dermatology, 9(3), 211-216. https://doi.org/10.1159/000481770
Garofalo, Virginia, et al. "Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases." Case reports in dermatology vol. 9,3 (2017): 211-216. doi: https://doi.org/10.1159/000481770
Garofalo V, Ventura A, Mazzilli S, Diluvio L, Bianchi L, Toti L, Tisone G, Milani M, Campione E. Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases. Case Rep Dermatol. 2017 Oct 20;9(3):211-216. doi: 10.1159/000481770. eCollection 2017. PMID: 29282394; PMCID: PMC5731151.
Copy Download .nbib Format: NLM
Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.

MedChemComm

Inceler N, Ozkan Y, Turan NN, Kahraman DC, Cetin-Atalay R, Baytas SN.
PMID: 30108969
Medchemcomm. 2018 Apr 06;9(5):795-811. doi: 10.1039/c8md00022k. eCollection 2018 May 01.

With the aim of achieving new compounds possessing both anti-inflammatory and antiplatelet activities, we synthesized (

Cite
Inceler N, Ozkan Y, Turan NN, et al. Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents. Medchemcomm. 2018;9(5):795-811doi: 10.1039/c8md00022k.
Inceler, N., Ozkan, Y., Turan, N. N., Kahraman, D. C., Cetin-Atalay, R., & Baytas, S. N. (2018). Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents. MedChemComm, 9(5), 795-811. https://doi.org/10.1039/c8md00022k
Inceler, Nazan, et al. "Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents." MedChemComm vol. 9,5 (2018): 795-811. doi: https://doi.org/10.1039/c8md00022k
Inceler N, Ozkan Y, Turan NN, Kahraman DC, Cetin-Atalay R, Baytas SN. Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents. Medchemcomm. 2018 Apr 06;9(5):795-811. doi: 10.1039/c8md00022k. eCollection 2018 May 01. PMID: 30108969; PMCID: PMC6072348.
Copy Download .nbib Format: NLM
Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus.

World journal of clinical pediatrics

Oncel MY, Erdeve O.
PMID: 26862505
World J Clin Pediatr. 2016 Feb 08;5(1):75-81. doi: 10.5409/wjcp.v5.i1.75. eCollection 2016 Feb 08.

Patent ductus arteriosus (PDA) is a common clinical condition in preterm infants which is inversely related to birth weight and gestational age. Cyclooxygenase inhibitors such as indomethacin and ibuprofen which block the prostaglandin conversion from arachidonic acid are the...

Cite
Oncel MY, Erdeve O. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World J Clin Pediatr. 2016;5(1):75-81doi: 10.5409/wjcp.v5.i1.75.
Oncel, M. Y., & Erdeve, O. (2016). Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World journal of clinical pediatrics, 5(1), 75-81. https://doi.org/10.5409/wjcp.v5.i1.75
Oncel, Mehmet Yekta, and Erdeve, Omer. "Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus." World journal of clinical pediatrics vol. 5,1 (2016): 75-81. doi: https://doi.org/10.5409/wjcp.v5.i1.75
Oncel MY, Erdeve O. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World J Clin Pediatr. 2016 Feb 08;5(1):75-81. doi: 10.5409/wjcp.v5.i1.75. eCollection 2016 Feb 08. PMID: 26862505; PMCID: PMC4737696.
Copy Download .nbib Format: NLM
Renal effects of prostaglandins and cyclooxygenase-2 inhibitors.

Electrolyte & blood pressure : E & BP

Kim GH.
PMID: 24459520
Electrolyte Blood Press. 2008 Jun;6(1):35-41. doi: 10.5049/EBP.2008.6.1.35. Epub 2008 Jun 30.

Prostaglandins (PGs) with best-defined renal functions are PGE2 and prostacyclin (PGI2). These vasodilatory PGs increase renal blood flow and glomerular filtration rate under conditions associated with decreased actual or effective circulating volume, resulting in greater tubular flow and secretion...

Cite
Kim GH. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press. 2008;6(1):35-41doi: 10.5049/EBP.2008.6.1.35.
Kim, G. H. (2008). Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte & blood pressure : E & BP, 6(1), 35-41. https://doi.org/10.5049/EBP.2008.6.1.35
Kim, Gheun-Ho. "Renal effects of prostaglandins and cyclooxygenase-2 inhibitors." Electrolyte & blood pressure : E & BP vol. 6,1 (2008): 35-41. doi: https://doi.org/10.5049/EBP.2008.6.1.35
Kim GH. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press. 2008 Jun;6(1):35-41. doi: 10.5049/EBP.2008.6.1.35. Epub 2008 Jun 30. PMID: 24459520; PMCID: PMC3894486.
Copy Download .nbib Format: NLM
Pharmacology of nonsteroidal antiinflammatory drugs and opioids.

Seminars in interventional radiology

Slater D, Kunnathil S, McBride J, Koppala R.
PMID: 22550382
Semin Intervent Radiol. 2010 Dec;27(4):400-11. doi: 10.1055/s-0030-1267855.

Chronic pain affects up to 50 million Americans every day. Traditional treatment has included acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), or opioids. The combination of NSAIDs and opioids can provide effective treatment for up to 90% of patients with chronic...

Cite
Slater D, Kunnathil S, McBride J, et al. Pharmacology of nonsteroidal antiinflammatory drugs and opioids. Semin Intervent Radiol. 2010;27(4):400-11doi: 10.1055/s-0030-1267855.
Slater, D., Kunnathil, S., McBride, J., & Koppala, R. (2010). Pharmacology of nonsteroidal antiinflammatory drugs and opioids. Seminars in interventional radiology, 27(4), 400-11. https://doi.org/10.1055/s-0030-1267855
Slater, Dick, et al. "Pharmacology of nonsteroidal antiinflammatory drugs and opioids." Seminars in interventional radiology vol. 27,4 (2010): 400-11. doi: https://doi.org/10.1055/s-0030-1267855
Slater D, Kunnathil S, McBride J, Koppala R. Pharmacology of nonsteroidal antiinflammatory drugs and opioids. Semin Intervent Radiol. 2010 Dec;27(4):400-11. doi: 10.1055/s-0030-1267855. PMID: 22550382; PMCID: PMC3324204.
Copy Download .nbib Format: NLM
Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma.

Veterinary and comparative oncology

Sorenmo KU, Goldschmidt MH, Shofer FS, Goldkamp C, Ferracone J.
PMID: 19379307
Vet Comp Oncol. 2004 Mar;2(1):13-23. doi: 10.1111/j.1476-5810.2004.00035.x.

Prostatic carcinoma occurs primarily in older castrated male dogs and is typically a fatal disease (most dogs die within few months after the initial diagnosis). Surgery, i.e., total prostatectomy, or radiation therapy is often not pursued due to risks...

Cite
Sorenmo KU, Goldschmidt MH, Shofer FS, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol. 2004;2(1):13-23doi: 10.1111/j.1476-5810.2004.00035.x.
Sorenmo, K. U., Goldschmidt, M. H., Shofer, F. S., Goldkamp, C., & Ferracone, J. (2004). Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Veterinary and comparative oncology, 2(1), 13-23. https://doi.org/10.1111/j.1476-5810.2004.00035.x
Sorenmo, K U, et al. "Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma." Veterinary and comparative oncology vol. 2,1 (2004): 13-23. doi: https://doi.org/10.1111/j.1476-5810.2004.00035.x
Sorenmo KU, Goldschmidt MH, Shofer FS, Goldkamp C, Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol. 2004 Mar;2(1):13-23. doi: 10.1111/j.1476-5810.2004.00035.x. PMID: 19379307.
Copy Download .nbib Format: NLM
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.

Therapeutics and clinical risk management

Mannaioni G, Baronti R, Moroni F.
PMID: 18360563
Ther Clin Risk Manag. 2005 Sep;1(3):225-30.

BACKGROUND: Neuroleptic malignant syndrome (NMS) is a rare side effect of antipsychotic therapy characterized by fever, muscular rigidity, altered mental status, increased level of serum creatinine phosphokinase, and increased number of white blood cells. The mortality rate of patients...

Cite
Mannaioni G, Baronti R, Moroni F. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Ther Clin Risk Manag. 2005;1(3):225-30
Mannaioni, G., Baronti, R., & Moroni, F. (2005). Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Therapeutics and clinical risk management, 1(3), 225-30.
Mannaioni, Guido, et al. "Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome." Therapeutics and clinical risk management vol. 1,3 (2005): 225-30.
Mannaioni G, Baronti R, Moroni F. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Ther Clin Risk Manag. 2005 Sep;1(3):225-30. PMID: 18360563; PMCID: PMC1661629.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 69 entries